Frank Verwiel
Chairman en INTELLIA THERAPEUTICS, INC. .
Fortuna: 388 985 $ al 31/03/2024
Perfil
Frank A. G. M. Verwiel es un empresario holandés que ha estado al frente de 6 empresas diferentes. Es presidente de ObsEva SA, presidente de Intellia Therapeutics, Inc. y presidente de Aptalis Pharma US, Inc. También forma parte del consejo de administración de Bavarian Nordic An y Bavarian Nordic GmbH. En su trayectoria profesional anterior, Frank A. G. M. Verwiel ocupó los cargos de vicepresidente de Hipertensión y Marketing Mundial de Salud Humana en Merck & Co., Inc., presidente, director general y consejero de Aptalis Pharma, Inc., presidente y director general de Aptalis Pharma SAS, presidente, director general y consejero de Aptalis Holdings, Inc. y director y consejero de la sección de salud de la Organización de Innovación Biotecnológica. Frank A. G. M. Verwiel obtuvo un MBA en INSEAD y un doctorado en la Universidad Erasmus de Rotterdam.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 14/06/2023 | 11 716 ( 0.01% ) | 322 307 $ | 31/03/2024 | |
BAVARIAN NORDIC A/S
0.00% | 31/12/2022 | 2 972 ( 0.00% ) | 66 678 $ | 31/03/2024 |
Cargos activos de Frank Verwiel
| Empresas | Cargo | Inicio |
|---|---|---|
| BAVARIAN NORDIC A/S | Director/Board Member | 20/04/2016 |
| INTELLIA THERAPEUTICS, INC. | Chairman | - |
Aptalis Pharma US, Inc.
 Aptalis Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Aptalis Pharma US, Inc. markets pharmaceutical products and services for the treatment of gastrointestinal diseases and disorders. It offers pancrelipase capsules, ursodiol tablets, porfimer sodium for injections, shake mixes, calorie boosters, clearance devices and multivitamin supplements. The firm also provides products for active ulcerative, liver diseases, pancreatic diseases, cystic fibrosis, chronic obstructive pulmonary disease, HIV/AIDS and cancer. The company was founded in 1991 and is headquartered in Wilmington, DE. | President | - |
Bavarian Nordic GmbH
 Bavarian Nordic GmbH BiotechnologyHealth Technology Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The private company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999. | Director/Board Member | 01/01/2016 |
Capsida Biotherapeutics, Inc.
 Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Director/Board Member | 01/08/2019 |
Antiguos cargos conocidos de Frank Verwiel.
| Empresas | Cargo | Fin |
|---|---|---|
| OBSEVA SA | Chairman | 18/05/2022 |
| ACHILLION PHARMACEUTICALS, INC. | Director/Board Member | 28/01/2020 |
| AVEXIS INC | Director/Board Member | 01/06/2018 |
| INTERMUNE INC | Director/Board Member | 01/09/2014 |
| ░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formación de Frank Verwiel.
| INSEAD | Masters Business Admin |
| Erasmus University Rotterdam | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| BAVARIAN NORDIC A/S | Health Technology |
| OBSEVA SA | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 10 |
|---|---|
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Aptalis Pharma LLC
 Aptalis Pharma LLC Pharmaceuticals: MajorHealth Technology Aptalis Pharma, Inc. develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology. The company's products include Zenpep, Canasa, Carafate, Pylera, Lacteal, Panzytrat, Delursan, Rectiv and Salofalk.. It provides therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. The company formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary pharmaceutical technology. Aptalis Pharma was founded 1982 and is headquartered in Birmingham, AL. | Health Technology |
Aptalis Pharma US, Inc.
Aptalis Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Aptalis Pharma US, Inc. markets pharmaceutical products and services for the treatment of gastrointestinal diseases and disorders. It offers pancrelipase capsules, ursodiol tablets, porfimer sodium for injections, shake mixes, calorie boosters, clearance devices and multivitamin supplements. The firm also provides products for active ulcerative, liver diseases, pancreatic diseases, cystic fibrosis, chronic obstructive pulmonary disease, HIV/AIDS and cancer. The company was founded in 1991 and is headquartered in Wilmington, DE. | Health Technology |
TA SASU
 TA SASU Pharmaceuticals: MajorHealth Technology Aptalis Pharma SAS is engaged in manufacturing pharmaceutical preparations. Its products include zenpep, canasa, carafate, pylera, rectiv, viokace, ultresa lacteol, delursan, panzytrat and salofalk. The company was founded in 1982 and is headquartered in Courbevoie, France. | Health Technology |
Aptalis Holdings, Inc.
 Aptalis Holdings, Inc. Pharmaceuticals: MajorHealth Technology Aptalis Holdings Inc. operates as a holding company that develops, manufactures, licenses, markets and distributes therapies for unmet medical needs. It includes cystic fibrosis and gastrointestinal disorders through its subsidiaries. It also formulates and clinically develops enhanced pharmaceutical, biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking and orally disintegration tablet formulations. The company was founded on January 10, 2008 and is headquartered in Bridgewater, NJ. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Commercial Services |
Bavarian Nordic GmbH
Bavarian Nordic GmbH BiotechnologyHealth Technology Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The private company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999. | Health Technology |
- Bolsa de valores
- Insiders
- Frank Verwiel
